Presentation is loading. Please wait.

Presentation is loading. Please wait.

Highlights of MACS and WIHS Protocol and Cohorts Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS.

Published byRichard Holmes Modified over 9 years ago

Similar presentations

Presentation on theme: "Highlights of MACS and WIHS Protocol and Cohorts Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS."— Presentation transcript:

1 Highlights of MACS and WIHS Protocol and Cohorts Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS Cohort Study or Women’s Interagency HIV Study

2 MACS Principal Investigators and Sites November 2004 Lisa Jacobson, CAMACS John Phair, Chicago Charles Rinaldo, Pittsburgh Roger Detels, Los Angeles Joe Margolick, Baltimore

3 WIHS Principal Investigators and Sites Alexandria Levine, Los Angeles Mary Young, District of Columbia Stephen Gange, WDMAC Ruth Greenblatt, San Francisco Mardge Cohen, Chicago Kathryn Anastos, Bronx Howard Minkoff, Brooklyn November 2004

4 Password protected MACS http://www.statepi.jhsph.edu/macs/ WIHS http://statepiaps.jhsph.edu/wihs/ Homemacs.htmlindex.html Dossierdossier/MACS_Dossier.pdfwihsdossier/dossier.ppt Archivesarchives.html Concept Formforms.htmlwihsconceptsheetsubform.doc Public Data Tapepdt.htmlPublicData/index.html Publication Policypubpolicy.html Directoryphp/dir_main.php http://www.statepi.jhsph.edu/php/ wihsdir/search.php Working Groupsphp/dir_main.php Formsforms.htmladmin/index.visitforms-moo.html May 2005

5 ► Behavioral - D. Ostrow ► Clinical - F. Palella ► Core Laboratory - C. Rinaldo & J. Margolick ► Data - L. Jacobson ► Malignancy/Pathology - O. Martinez-Maza ► Metabolic/Cardiovascular - L. Kingsley ► Neuropsychology - E. Miller ► Viral Hepatitis - C. Thio MACS Working Groups - Chairs November 2004

6 WIHS Scientific Working Groups - Chairs ► Aging/Neurocognitive – M. Young ► Behavior/Drug Use – T. Wilson / D. Vlahov ► Cancer/Pathology – N. Hessol ► Cardiovascular – R. Kaplan ► Epidemiology – A. French ► GYN – H. Minkoff ► Hepatitis – M. Peters ► HIV Virology - B. Weiser ► HPV – H. Strickler ► Immunology - L. Al-Harthi ► Laboratory/Specimen – W. Meyer ► Metabolic – P. Tien ► Pharmacology - R. Greenblatt ► Statistical/Analytical – A. Kalinowski May 2005

7 MACS / WIHS Cohort: Summary MACSWIHS Study designProspective cohort Follow-up visitsSemi-annual Data collection sitesBaltimore/DC, Chicago, Los Angeles, Pittsburgh Bronx, Brooklyn, Chicago, DC, Los Angeles, San Francisco Data centerJohns Hopkins Univ. Date started19841994 Current visit (4/05 – 9/05) 4322 Outcome ascertainment (active and passive) Medically confirmed Total enrolled6,9733,768 May 2005

8 Semiannual Visit ► Medications Antivirals, OI-specific, adherence ► Physical Examination / GYN ( WIHS ) Anthropomorphic/ lipodystrophy measures Hand grip / timed walk ( MACS v43.5; WIHS v22 ) ► Questionnaire / ACASI ( MACS ) Medical History, Health Services, Behavior Demographics / Psychosocial Quality of Life ► Neuropsychological Screening ► Specimens and Labs Plasma, Serum, Cells, CVL ( WIHS ), Hair ( WIHS HIV+ ) T-cells, HIV RNA, HBV & HCV serology, lipids B-cell lines, National Repository May 2005

9 Continuous Outcome Ascertainment ► Seroconversion ► Clinical Outcomes (medical record confirmation) AIDS diagnoses Non-AIDS diagnoses  Cardiovascular disease  Cerebrovascular disease  Kidney disease (MACS)  Liver disease  Lung infection, bacterima, septicemia (MACS), TB (WIHS)  Malignancies  Neurologic ► Mortality and cause of death November 2004

10 MACSWIHS Total enrolled6,9733,768 Seropositives - Prevalent - Incident 3,501 2,884 617 2,809 2,793 16 AIDS cases - Prevalent - Incident 1,843 11 1,832 1,364 715 649 Number of deaths1,897 712 Number of HAART users since 1/951,3271,891 Alive & active since 4/032,7542,416 - HIV+, AIDS (HAART) - HIV+, AIDS-free (HAART) - HIV- 176 (174) 1,096 (893) 1,482 655 (589) 1,071 (858) 690 Descriptive Statistics May 2005

11 MACSWIHS HIV+HIV-HIV+HIV- Total Participants3,5013,4722,809959 Person-years27,92540,50214,9324,545 Person-visits44,82259,91129,5719,085 CD4 measurements41,83246,29528,1036,436 HIV RNA measurements23,2551,14727,992 -- Repository aliquots*842,2311,495,589 MACS/WIHS Database May 2005 *Available as of 5/9/2005

12 MACSWIHS Pre-20012001-3OverallPre-20012001-2Overall % Seropositive405342786574 % Non-white177228829185 % < high school21653738 % > college563151787 Median age (IQR) 33 (28; 38) 38 (32; 43) 34 (29; 39) 36 (30; 41) 31 (26; 37) 34 (29; 40) Demographics of MACS/WIHS Cohorts: Baseline November 2004

13 Overall MACS (n=1316) Overall WIHS (n=1652) CD4 (cells/  l) Med (IQR) 488 (332; 673) 418 (266; 624) CD8 (cells/  l) Med (IQR) 889 (644; 1,185) 785 (554; 1,078) HIV RNA Med (IQR) 65 (<50; 9,242) 475 (<80; 12,000) HIV Disease Markers at Most Recent Visit: Current MACS/WIHS Cohorts November 2004

14 Antiretroviral Therapy Use Among Seropositives Calendar Time May 2005 NRTI MonotherapyNRTI Combination Therapy HAART no PI HAART with PI MACS 0 20 40 60 80 100 19951997199920012003 19951997199920012003 WIHS

15 Age Distribution among Active HIV+ MACS & WIHS Participants May 2005

16 Age Distribution among Active HIV- MACS & WIHS Participants May 2005

17 HAART Use in the MACS/WIHS Cohorts May 2005 96-197-198-199-100-101-102-103-104-1 0 20 40 60 80 100 Calendar (Year-Semester) Incidence of HAART per 100 P-SEM MACS Incidence RateMACS Cumulative Incidence WIHS Incidence RateWIHS Cumulative Incidence

Download ppt "Highlights of MACS and WIHS Protocol and Cohorts Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS."

Similar presentations

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.
DOSSIER Web site: Prepared by CAMACS Fax: 410-955-7587 May 2011 The MACS.

DOSSIER Web site: Prepared by CAMACS Fax: May 2011 The MACS.
DACS 272 Neurologic deficits in the years following ART initiation among subjects in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized.

DACS 272 Neurologic deficits in the years following ART initiation among subjects in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized.
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.

An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,

Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,

Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.
PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.

PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.
The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.

The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.
Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.

Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
HIV Care Continuum for the United States and Puerto Rico National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.

HIV Care Continuum for the United States and Puerto Rico National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
Antiretroviral Therapy Exposure and Insulin Resistance in the Women’s Interagency HIV Study Phyllis C. Tien MD 1, Michael F. Schneider MS 2, Stephen R.

Antiretroviral Therapy Exposure and Insulin Resistance in the Women’s Interagency HIV Study Phyllis C. Tien MD 1, Michael F. Schneider MS 2, Stephen R.
First-Line HIV Therapy and Treatment Strategies: A Summary of Key CROI 2008 Research First-Line HIV Therapy and Treatment Strategies The Body PRO Coverage.

First-Line HIV Therapy and Treatment Strategies: A Summary of Key CROI 2008 Research First-Line HIV Therapy and Treatment Strategies The Body PRO Coverage.
* Pre- and Post-HAART eras defined as before or after 07/01/96. ** For comparison of HIV positive to HIV negative IRs within Pre- or Post-HAART eras. ***

* Pre- and Post-HAART eras defined as before or after 07/01/96. ** For comparison of HIV positive to HIV negative IRs within Pre- or Post-HAART eras. ***
Web site: Prepared by CAMACS Fax: 410-955-7587 May 2011 The MACS is funded by the National Institute of Allergy.

Web site: Prepared by CAMACS Fax: May 2011 The MACS is funded by the National Institute of Allergy.
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.

Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
HIV and STI Department - Centre for Infections Predictors of non-AIDS related death in a national cohort of HIV-diagnosed adults Meaghan Kall, Ruth Smith,

HIV and STI Department - Centre for Infections Predictors of non-AIDS related death in a national cohort of HIV-diagnosed adults Meaghan Kall, Ruth Smith,
Proposed study on HIV and ageing As HIV mortality rates have dropped, an increasing proportion of individuals are living with HIV to older ages As HIV.

Proposed study on HIV and ageing As HIV mortality rates have dropped, an increasing proportion of individuals are living with HIV to older ages As HIV.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.

Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
Texas Medical Monitoring Project (MMP) Meeting Omni Austin Hotel at Southpark Thursday, May 31, 2007 a multi-stage probability sample of HIV infected adults.

Texas Medical Monitoring Project (MMP) Meeting Omni Austin Hotel at Southpark Thursday, May 31, 2007 a multi-stage probability sample of HIV infected adults.

Similar presentations

Ads by Google